Pierre Fabre Laboratories and Iktos, a global leader in AI-driven drug discovery, announced a strategic collaboration to develop new small-molecule drug candidates for oncology. The partnership combines Iktos’ expertise in generative AI and automated chemistry with Pierre Fabre’s extensive knowledge in oncology research, medicinal chemistry, biology, and preclinical development to accelerate the discovery and optimization of innovative cancer therapies.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
Under the agreement, Iktos will apply its AI-powered generative design platform to identify promising small-molecule candidates against a currently undisclosed oncology target. Pierre Fabre Laboratories will guide the evaluation, selection, and preclinical progression of the candidates, leveraging its deep scientific and clinical development capabilities. Financial terms were not disclosed but include an upfront payment and milestone-based commitments.
Audrey Kauffmann, Head of Data Science and Biometry at Pierre Fabre Medical Care R&D, highlighted that this collaboration represents a major step in building an AI-enhanced research and development engine at Pierre Fabre Laboratories. She explained that integrating Iktos’ AI and automated chemistry technologies into their platforms advances the company’s data and AI strategy and supports the goal of increasing the efficiency and success rate of oncology drug discovery while bringing faster therapeutic advances to patients.
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
Olivier Geneste, Head of Drug Discovery at Pierre Fabre Medical Care R&D, said the partnership provides a unique opportunity to accelerate and de-risk the discovery of highly innovative therapeutics. He noted that Iktos’ established capabilities in generative AI combined with automated chemistry will allow Pierre Fabre to target a valuable oncology area with high unmet medical need, ultimately benefiting patients.
Yann Gaston-Mathé, Co-founder and CEO of Iktos, emphasized that the collaboration demonstrates the complementarity between Iktos’ technology and Pierre Fabre’s scientific expertise. He explained that together they will create an efficient framework to rapidly progress new small-molecule candidates through the discovery process and aim to deliver meaningful cancer therapies to patients worldwide.
The partnership underscores both companies’ commitment to combining cutting-edge technology with deep scientific knowledge to transform oncology drug discovery and bring innovative solutions to patients in need.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
